Loading…
TransCode Therapeutics, Inc. is projected to decline to $3.91 by 2027, a -7% move from its current price of $4.22. RNAZ is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $3.91 | $4.22 | $4.56 | +0.05% |
| Aug 6 | $3.79 | $4.22 | $4.71 | +0.10% |
| Aug 7 | $3.70 | $4.23 | $4.82 | +0.14% |
| Aug 8 | $3.63 | $4.23 | $4.93 | +0.19% |
| Aug 9 | $3.57 | $4.23 | $5.02 | +0.24% |
| Aug 10 | $3.51 | $4.23 | $5.10 | +0.29% |
| Aug 11 | $3.46 | $4.23 | $5.18 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.46 | $4.23 | $5.18 | +0.33% |
| Week 2 | $3.19 | $4.25 | $5.65 | +0.67% |
| Week 3 | $3.00 | $4.26 | $6.05 | +1.01% |
| Week 4 | $2.85 | $4.28 | $6.41 | +1.34% |
| Week 5 | $2.73 | $4.29 | $6.74 | +1.68% |
| Week 6 | $2.62 | $4.31 | $7.06 | +2.02% |
| Week 7 | $2.53 | $4.32 | $7.37 | +2.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TransCode Therapeutics, Inc. is a clinical-stage company that develops immuno-oncology and RNA therapeutics for high risk and advanced cancers. Its therapeutic candidate SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc.
has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
RNAZ is the trading symbol for TransCode Therapeutics, Inc. It is currently priced at $4.56 with a market cap of $4.83M and is ranked 5290 by market capitalization. The price outlook is mixed, with forecasted averages varying by year and a long-run path toward modest to notable gains in the 2040s and beyond.
The forward-looking numbers imply a cautious near-term path and a potential longer-term upside, though outcomes are uncertain.
A major floor 71.8% below — a decisive break under it would weaken the trend.
Support has flipped 7.8% overhead — reclaiming it would be bullish.
The nearest ceiling, 127.4% above — a clean break opens room to run.
A major ceiling 167.3% above — clearing it would confirm fresh momentum.
Key RNAZ support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNAZ market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.04 | Sell | $5.24 | Sell |
| MA 10 | $6.39 | Sell | $5.99 | Sell |
| MA 20 | $7.45 | Sell | $6.57 | Sell |
| MA 50 | $6.30 | Sell | $6.80 | Sell |
| MA 100 | $7.35 | Sell | $7.60 | Sell |
| MA 200 | $8.50 | Sell | $248.33 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.49 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -140.15 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.48 | Sell |
| ROC (12) | -47.56 | Sell |
| Bollinger %B (20,2) | 0.04 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | -1.64 | Sell |
| Ultimate (7,14,28) | 15.07 | Buy |
| Momentum (10) | -3.87 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 4.32 | Sell |
| ADX (14) | 25.13 | Sell |
| ATR (14) | 0.49 | Info |
The 30-day technical picture is bearish. RSI(14) is 30, and the stock trades below both the SMA50 and SMA200, which stand at $6.30 and $8.50 respectively. Immediate support is at $4.55 and resistance at $9.60. The 30-day price range spans from $2.76 to $7.54.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.22 | $4.22 | $5.24 | 0% | Neutral | |
| $2.85 | $3.91 | $5.80 | -7% | Neutral | |
| $2.34 | $3.42 | $5.41 | -19% | Bearish | |
| $2.22 | $3.41 | $5.67 | -19% | Bearish | |
| $1.93 | $3.12 | $5.40 | -26% | Bearish | |
| $1.90 | $3.20 | $5.74 | -24% | Bearish | |
| $2.53 | $4.45 | $8.23 | +6% | Neutral | |
| $2.74 | $5.01 | $9.52 | +19% | Neutral | |
| $2.61 | $4.98 | $9.71 | +18% | Neutral | |
| $2.21 | $4.37 | $8.72 | +4% | Neutral | |
| $3.22 | $7.15 | $15.69 | +70% | Bullish | |
| $3.83 | $8.52 | $19.59 | +102% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.22 | $4.22 | $5.09 | +0.00% |
| September 2026 | $3.47 | $4.22 | $5.35 | -0.10% |
| October 2026 | $3.58 | $4.41 | $5.70 | +4.55% |
| November 2026 | $3.39 | $4.22 | $5.55 | -4.19% |
| December 2026 | $3.12 | $3.93 | $5.24 | -6.95% |
Click any year to see its month-by-month RNAZ forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RNAZ is projected to trade between $4.22 and $5.24, averaging $4.22 — a potential gain of 0% from today's $4.22. Price action looks broadly range-bound.
TransCode Therapeutics, Inc.'s 2027 outlook centres on $3.91, within a $2.85 to $5.80 range. That is -7% versus the projected 2026 average. That marks a -7% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, RNAZ could reach as high as $5.41, with a base case around $3.42 and support toward $2.34 — roughly -19% from $4.22. A cyclical pullback looks likely — prices rarely move in a straight line.
Expect RNAZ to range from $2.22 to $5.67 through 2029. The $3.41 average target implies a -19% move from current prices. That is 0% versus the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
The RNAZ price prediction for 2030 points to an average of $3.12 (low $1.93, high $5.40) — a potential decline of -26% on today's $4.22. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2031, RNAZ is projected to trade between $1.90 and $5.74, averaging $3.20 — a potential decline of -24% from today's $4.22. That is up +3% on the projected 2030 average. Expect choppier, lower action through this leg of the cycle.
TransCode Therapeutics, Inc.'s 2032 outlook centres on $4.45, within a $2.53 to $8.23 range. That is up +39% on the projected 2031 average. That marks a +6% change versus current levels. Price action looks broadly range-bound.
By 2033, RNAZ could reach as high as $9.52, with a base case around $5.01 and support toward $2.74 — roughly +19% from $4.22. A consolidation phase looks the most probable path here.
Expect RNAZ to range from $2.61 to $9.71 through 2034. The $4.98 average target implies a +18% move from current prices. That is -1% versus the projected 2033 average. Price action looks broadly range-bound.
The RNAZ price prediction for 2035 points to an average of $4.37 (low $2.21, high $8.72) — a potential gain of +4% on today's $4.22. A consolidation phase looks the most probable path here.
In 2040, RNAZ is projected to trade between $3.22 and $15.69, averaging $7.15 — a potential gain of +70% from today's $4.22. That is up +64% on the projected 2035 average. Momentum favours further upside here.
TransCode Therapeutics, Inc.'s 2050 outlook centres on $8.52, within a $3.83 to $19.59 range. That is up +19% on the projected 2040 average. That marks a +102% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in RNAZ today (≈ 236.966825 RNAZ) could be worth
$2,018.75
+$1,018.75 (+102%) by 2050 · US Dollar
Based on the average projected RNAZ price of $8.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNAZwould be worth at today's price.
$1,000 invested in RNAZ on Jul 31, 2025 (≈ 90.090087 RNAZ) would be worth
$380.18
-$619.82 (-62.0%) today · 0.38× · US Dollar
Based on a RNAZ entry price of $11.1 vs. today's $4.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.93 | $711.64 | -28.8% |
| 1 month ago | $7.65 | $551.63 | -44.8% |
| 3 months ago | $7.83 | $538.95 | -46.1% |
| 6 months ago | $9.3 | $453.76 | -54.6% |
| 1 year ago | $11.1 | $380.18 | -62.0% |
| All time (5.0y) ago | $2,454,144 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNAZ forecast.
Our base-case forecast reaches $8.40 around 2050.
Implied market cap at $8.40: $8.89M
The multi-year forecast shows a mixed to improving trajectory after an initial downturn. In 2026 the average price is $4.56 with a neutral sentiment and 0% ROI. In 2027 the average is $4.23 with a neutral sentiment and -7.2% ROI, followed by 2028 at $3.69 with -19.1% ROI and bearish sentiment, and 2029 at $3.68 with -19.3% ROI and bearish sentiment.
By 2030 the average is $3.38 with -25.9% ROI and bearish sentiment, and 2031 at $3.45 with -24.3% ROI and bearish sentiment. The trajectory improves in 2032 to an average of $4.82 (5.7% ROI, neutral sentiment), then 2033 at $5.42 (18.9% ROI, neutral), 2034 at $5.36 (17.6% ROI, neutral), and 2035 at $4.73 (3.6% ROI, neutral). In 2040 the average climbs to $7.72 with a 69.2% ROI and bullish sentiment, and by 2050 the average reaches $9.19 with a 101.6% ROI and bullish sentiment.
Tap a question to reveal the answer.
The forecast shows an average price of $3.38, with a low of $2.09 and a high of $5.85; ROI -25.9%; sentiment BEARISH.
The outlook is mixed: neutral in 2026 and 2027, then bearish through 2031, followed by neutral to bullish later years. Notably, 2040 shows an average of $7.72 with a 69.2% ROI and bullish sentiment, and 2050 shows an average of $9.19 with a 101.6% ROI and bullish sentiment.
Yes. The forecast maximums show $10.31 in 2033 and $10.45 in 2034.
Current price is $4.56 and market cap is $4.83M.
Bearish sentiment with RSI(14) at 30. SMA50 is $6.30 and SMA200 is $8.50. Support is $4.55 and resistance is $9.60. The 30-day range is from $2.76 to $7.54.
TransCode Therapeutics, Inc. Community Discussion
0Share your TransCode Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.